Results 201 to 206 of about 824,117 (206)

Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents

Bioorganic and Medicinal Chemistry Letters, 2010
Yan Zhang, David A Gewirtz, Zendra E Zehner   +2 more
exaly  

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

Journal of Acquired Immune Deficiency Syndromes, 2011
J. Lalezari, J. Gathe, C. Brinson, M. Thompson, C. Cohen, E. Dejesus, J. Galíndez, J. Ernst, David E. Martin, S. Palleja   +9 more
semanticscholar   +1 more source

Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection

Expert Opinion on Investigational Drugs, 2009
Clara Lehmann, Gerd Fätkenheuer
exaly  

People also looked at

Frontiers in Immunology, 2015
Elna van der Ryst
exaly  

SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV

Drug Metabolism And Disposition, 2005
D. Walker, S. Abel, P. Comby, G. Muirhead, A. Nedderman, Dennis A. Smith   +5 more
semanticscholar   +1 more source

A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation

Cancer Letters
Fang Wu, Jing Yu, Ling Chen
exaly